Aim: To assess the effects of diabetes mellitus (DM) and related variables on surgical site infection (SSI) risk in neuromodulation. Methods: This retrospective study followed patients who underwent neuromodulation procedures for at least 9 months to identify postoperative infections. Demographics, clinical characteristics and surgical outcomes were compared. Results: Of 195 cases included, 5 (2.6%) resulted in SSIs. Median HbA1c was significantly higher for the cases with SSIs (8.2 vs 5.6%; p = 0.0044). The rate of SSI was significantly higher among patients with DM (17.9 vs 0%; p = 0.0005), HbA1c≥7% (37.5 vs 0%; p = 0.0009), and perioperative glucose ≥200 mg/dl (40 vs 2.3%; p = 0.0101). Conclusion: DM, elevated HbA1c and perioperative hyperglycemia may all contribute to increased risk of SSIs with neuromodulation procedures.

Plain language summary

Infections are feared complications of surgery. It is important to identify factors that increase the risk of infection to prevent these complications. This study looked at the effects of diabetes and high blood sugar on the risk of infection associated with pain procedures. The researchers followed patients who had these procedures and looked for any infections that occurred afterward. They found that patients with diabetes and high blood sugar levels before surgery were more likely to develop infections after these procedures. More research can help establish blood sugar targets so that physicians can better manage this risk for their patients.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Manca A, Kumar K, Taylor RS et al. Quality of life, resource consumption and costs of spinal cord stimulation versus conventional medical management in neuropathic pain patients with failed back surgery syndrome (PROCESS trial). Eur. J. Pain 12(8), 1047–1058 (2008).
MedlineGoogle Scholar
2. World Health Organization. Global guidelines for the prevention of surgical site infection. 2nd Edition, World Health Organization, Geneva (2018). • These are among the most widely used and cited surgical guidelines for infection prevention.
Google Scholar
3. Berríos-Torres SI, Umscheid CA, Bratzler DW et al. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. JAMA Surg. 152(8), 784–791 (2017). • These are among the most widely used and cited surgical guidelines for infection prevention.
MedlineGoogle Scholar
4. Rosenberger LH, Politano AD, Sawyer RG. The surgical care improvement project and prevention of post-operative infection, including surgical site infection. Surg. Infect. 12(3), 163–168 (2011). • These are among the most cited surgical guidelines for infection prevention.
MedlineGoogle Scholar
5. Zhang Y, Zheng QJ, Wang S et al. Diabetes mellitus is associated with increased risk of surgical site infections: a meta-analysis of prospective cohort studies. Am. J. Infect. Control 43(8), 810–815 (2015).
MedlineGoogle Scholar
6. Martin E, Kaye K, Knott C et al. Diabetes and Risk of Surgical Site Infection: A Systematic Review and Meta-analysis. Infect. Control Hosp. Epidemiol. 37(1), 88–99 (2016).
MedlineGoogle Scholar
7. Kwon S, Thompson R, Dellinger P, Yanez D, Farrohki E, Flum D. Importance of perioperative glycemic control in general surgery: a report from the Surgical Care and Outcomes Assessment Program. Ann. Surg. 257(1), 8–14 (2013).
MedlineGoogle Scholar
8. Latham R, Lancaster A, Covington J, Pirolo J, Thomas C. The Association of Diabetes and Glucose Control With Surgical-Site Infections Among Cardiothoracic Surgery Patients. Infect. Control Hosp. Epidemiol. 22(10), 607–612 (2001).
Medline CASGoogle Scholar
9. Olsen MA, Nepple JJ, Riew KD et al. Risk factors for surgical site infection following orthopaedic spinal operations. J. Bone Joint Surg. Am. 90(1), 62–69 (2008).
MedlineGoogle Scholar
10. Vriesendorp TM, Morelis QJ, Devries JH et al. Early post-operative glucose levels are an independent risk factor for infection after peripheral vascular surgery. A retrospective study. Eur. J. Vasc. Endovasc. Surg. 28, 520–525 (2004).
Medline CASGoogle Scholar
11. McGirt MJ, Woodworth GF, Brooke BS et al. Hyperglycemia independently increases the risk of perioperative stroke, myocardial infarction, and death after carotid endarterectomy. Neurosurgery 58, 1066–1073 (2006).
MedlineGoogle Scholar
12. Hikata T, Iwanami A, Hosogane N et al. High preoperative hemoglobin A1c is a risk factor for surgical site infection after posterior thoracic and lumbar spinal instrumentation surgery. J. Orthop. Sci. 19(2), 223–228 (2014).
Medline CASGoogle Scholar
13. Stryker LS, Abdel MP, Morrey ME, Morrow MM, Kor DJ, Morrey BF. Elevated postoperative blood glucose and preoperative hemoglobin A1 C are associated with increased wound complications following total joint arthroplasty. J. Bone Joint Surg. 95(9), S808–S2 (2013).
MedlineGoogle Scholar
14. Tarabichi M, Shohat N, Kheir MM et al. Determining the Threshold for HbA1c as a Predictor for Adverse Outcomes After Total Joint Arthroplasty: A Multicenter, Retrospective Study. J. Arthroplasty 32(9S), S263–S267.e1 (2017).
MedlineGoogle Scholar
15. Zukowska A, Zukowski M. Surgical Site Infection in Cardiac Surgery. J. Clinical Med. 11(23), 6991 (2022).
Medline CASGoogle Scholar
16. Worley N, Buza J, Jalai CM et al. Diabetes as an Independent Predictor for Extended Length of Hospital Stay and Increased Adverse Post-Operative Events in Patients Treated Surgically for Cervical Spondylotic Myelopathy. Int. J. Spine Surg. 11(2), 10 (2017).
MedlineGoogle Scholar
17. Smith DK, Bowen J, Bucher L et al. A study of perioperative hyperglycemia in patients with diabetes having colon, spine, and joint surgery. J. Perianesth. Nurs. 24(6), 362–369 (2009).
MedlineGoogle Scholar
18. Bendel MA, O'Brien T, Hoelzer BC et al. Spinal Cord Stimulator Related Infections: Findings From a Multicenter Retrospective Analysis of 2737 Implants. Neuromodulation 20, 553–557 (2017).
MedlineGoogle Scholar
19. Deer TR, Mekhail N, Provenzano D et al. The appropriate use of neurostimulation: avoidance and treatment of complications of neurostimulation therapies for the treatment of chronic pain. Neuromodulation 17, 571–598 (2014).
MedlineGoogle Scholar
20. Turner JA, Loeser JD, Deyo RA, Sanders SB. Spinal cord stimulation for patients with failed back surgery syndrome or complex regional pain syndrome: a systematic review of effectiveness and complications. Pain 108, 137–147 (2004).
MedlineGoogle Scholar
21. Cameron T. Safety and efficacy of spinal cord stimulation for the treatment of chronic pain: a 20-year literature review. J. Neurosurg. 100, 254–267 (2004).
MedlineGoogle Scholar
22. Follett KA, Boortz-Marx RL, Drake JM et al. Prevention and management of intrathecal drug delivery and spinal cord stimulation system infections. Anesthesiology 100, 1582–1594 (2004).
MedlineGoogle Scholar
23. Maldonado-Naranjo AL, Frizon LA, Sabharwal NC et al. Rate of Complications Following Spinal Cord Stimulation Paddle Electrode Removal. Neuromodulation 21(5), 513–519 (2018).
MedlineGoogle Scholar
24. Arocho-Quinones EV, Huang CC, Ward BD, Pahapill PA. Care Bundle Approach to Minimizing Infection Rates after Neurosurgical Implants for Neuromodulation: A Single-Surgeon Experience. World Neurosurg. 128, e87–e97 (2019).
MedlineGoogle Scholar
25. Engle MP, Vinh BP, Harun N, Koyyalagunta D. Infectious complications related to intrathecal drug delivery system and spinal cord stimulator system implantations at a comprehensive cancer pain center. Pain Physician 16(3), 251–257 (2013).
MedlineGoogle Scholar
26. Stearns LM, Abd-Elsayed A, Perruchoud C et al. Intrathecal Drug Delivery Systems for Cancer Pain: An Analysis of a Prospective, Multicenter Product Surveillance Registry. Anesth. Analg. 130(2), 289–297 (2020).
MedlineGoogle Scholar
27. Darouiche RO. Treatment of infections associated with surgical implants. N. Engl. J. Med. 350, 1422–1429 (2004).
Medline CASGoogle Scholar
28. Deer TR, Provenzano DA, Hanes M et al. The Neurostimulation Appropriateness Consensus Committee (NACC) Recommendations for Infection Prevention and Management [published correction appears in Neuromodulation 2017; 20(5): 516]. Neuromodulation 20(1), 31–50 (2017). •• These are the only pain-centered infection prevention guidelines currently available.
MedlineGoogle Scholar
29. Hoelzer BC, Bendel MA, Deer TR et al. Spinal cord stimulator implant infection rates and risk factors: a multicenter retrospective study. Neuromodulation 20, 558–562 (2017).
MedlineGoogle Scholar
30. Provenzano DA, Keith AD, Kilgore JS. Prevalence of Staphylococcus aureus Colonization in Spinal Cord Stimulator Surgical Procedures [published online ahead of print, 2022 Jun 8]. Neuromodulation, S1094-7159(22)00684-5 (2022).
Google Scholar
31. Mekhail NA, Mathews M, Nageeb F, Guirguis M, Mekhail MN, Cheng J. Retrospective review of 707 cases of spinal cord stimulation: indications and complications. Pain Pract. 11, 148–153 (2011).
MedlineGoogle Scholar
32. Falowski SM, Provenzano DA, Xia Y, Doth AH. Spinal Cord Stimulation Infection Rate and Risk Factors: Results From a United States Payer Database. Neuromodulation 22(2), 179–189 (2019).
MedlineGoogle Scholar
33. Daniels DH, Powell CR, Braasch MR, Kreder KJ. Sacral neuromodulation in diabetic patients: success and complications in the treatment of voiding dysfunction. Neurourol. Urodyn. 29(4), 578–581 (2010).
MedlineGoogle Scholar
34. Nicolotti D, Iotti E, Fanelli G, Compagnone C. Perineural catheter infection: a systematic review of the literature. J. Clin. Anesth. 35, 123–128 (2016).
MedlineGoogle Scholar
35. Kotagal M, Symons RG, Hirsch IB et al. Perioperative hyperglycemia and risk of adverse events among patients with and without diabetes. Ann. Surg. 261(1), 97–103 (2015).
MedlineGoogle Scholar
36. Shoji H, Hirano T, Watanabe K, Ohashi M, Mizouchi T, Endo N. Risk factors for surgical site infection following spinal instrumentation surgery. J. Orthop. Sci. 23(3), 449–454 (2018).
MedlineGoogle Scholar
37. Burgess JL, Wyant WA, Abdo Abujamra B, Kirsner RS, Jozic I. Diabetic Wound-Healing Science. Medicina (Kaunas) 57(10), 1072 (2021).
MedlineGoogle Scholar
38. Peleg AY, Weerarathna T, McCarthy JS, Davis TM. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab. Res. Rev. 23(1), 3–13 (2007).
Medline CASGoogle Scholar
39. Joshi GP, Chung F, Vann MA et al. Society for Ambulatory Anesthesia consensus statement on perioperative blood glucose management in diabetic patients undergoing ambulatory surgery. Anesth. Analg. 111(6), 1378–1387 (2010).
MedlineGoogle Scholar
40. Lazar HL, McDonnell M, Chipkin SR et al. The Society of Thoracic Surgeons practice guideline series: blood glucose management during adult cardiac surgery. Ann. Thorac. Surg. 87(2), 663–669 (2009).
MedlineGoogle Scholar
41. American Diabetes Association. 14. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2018. Diabetes Care 41(Suppl. 1), S144–S151 (2018).
MedlineGoogle Scholar
42. Hagedorn JM, Bendel MA, Hoelzer BC, Aiyer R, Caraway D. Preoperative hemoglobin A1c and perioperative blood glucose in patients with diabetes mellitus undergoing spinal cord stimulation surgery: a literature review of surgical site infection risk. Pain Pract. 23(1), 83–93 (2023).
MedlineGoogle Scholar
43. Michel M, Lucke-Wold B. Diabetes management in spinal surgery. J. Clin. Images Med. Case Rep. 3(6), 1906 (2022).
Google Scholar
44. American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2018. Diabetes Care 41, S55–S64 (2018).
MedlineGoogle Scholar
45. Cancienne JM, Werner BC, Chen DQ, Hassanzadeh H, Shimer AL. Perioperative hemoglobin A1c as a predictor of deep infection following single-level lumbar decompression in patients with diabetes. Spine J. 17(8), 1100–1105 (2017).
MedlineGoogle Scholar
46. Dronge AS, Perkal MF, Kancir S, Concato J, Aslan M, Rosenthal RA. Long-term glycemic control and postoperative infectious complications. Arch. Surg. 141(4), 375–380 (2006).
MedlineGoogle Scholar
47. Petersen EA, Stauss TG, Scowcroft JA et al. Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: A Randomized Clinical Trial. JAMA Neurol. 78(6), 687–698 (2021).
MedlineGoogle Scholar

Vol. 13, No. 7

Metrics

Downloaded 45 times

History

Received 6 May 2023

Accepted 6 July 2023

Published online 28 July 2023

Published in print July 2023

Information

Keywords

Author contributions

BK Huh, A Huh, S Javed and E Ege were involved in study conception. S Javed, E Ege and D Briggi contributed to data collection and analysis. All authors contributed to the drafting and final approval of the manuscript.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval for all human or animal experimental investigations. As this was a retrospective study, the requirement for informed consent was waived by the institutional review board.

PDF download